COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,547 Articles (22,881 medRxiv, 8,666 bioRxiv)

Most recent first Previous |  Page 581: Articles 5801-5810  | Next

Non-generalizability of biomarkers for mortality in SARS-CoV-2: a meta-analyses series
Shuvo, M. R., Schweining, M., Soares, F., Feng, O., Abreu, S., Veale, N., Thomas, W., Thompson, A. R., Samworth, R., Morrell, N. W., Marciniak, S., Soon, E.
10.1101/2022.12.03.22282974 — Posted: 2022-12-07
Emergence and antibody evasion of BQ and BA.2.75 SARS-CoV-2 sublineages in the face of maturing antibody breadth at the population level
Akerman, A., Milogiannakis, V., Jean, T., Esneu, C., Ruiz Silva, M., Ison, T., Fichter, C., Chandra, D., Naing, Z., Walker, G., Caguicla, J., Li, d., Amatayakul-Chantler, S., Manni, S., Roth, N., Hauser, T., Condylios, A., Yeang, M., Wong, M., Foster, C. S. P., Lee, S., Song, Y., Mao, L., Phu, A., Sigmund, A., Van de More, A. M., Hunt, S., Sandgren, K., Bull, R., Lloyd, A., Triccas, J., Tangye, S., Cunningham, A. L., Bartlett, N. W., Darley, D., Matthews, G., Douglas, M., Caterson, I., Rawlinson, W. D., Brilot, F., Stark, D. J., Kelleher, A. D., Aggarwal, A., Turville, S. G.
10.1101/2022.12.06.22283000 — Posted: 2022-12-07
Lack of effectiveness of Bebtelovimab Monoclonal Antibody Among High-Risk Patients with SARS-Cov-2 Omicron During BA.2, BA.2.12.1 and BA.5 Subvariants Dominated Era
Sridhara, S., Gungor, A. B., Erol, H. K., Al-Obaidi, M., Zangeneh, T., Bedrick, E., Ariyamuthu, V., Shetty, A., Qannus, A. A., Mendoza, K., Murugapandian, S., Gupta, G., Tanriover, B.
10.1101/2022.12.06.22283183 — Posted: 2022-12-07
Increased migratory/activated CD8+ T cell and low avidity SARS-CoV-2 reactive cellular response in post-acute COVID-19 syndrome
Paniskaki, K., Konik, M., Anft, M., Heidecke, H., Meister, T., Pfaender, S., Krawczyk, A., Zettler, M., Jäger, J., Gaeckler, A., Dolff, S., Westhoff, T., Rohn, H., Stervbo, U., Scheibenbogen, C., Witzke, O., Babel, N.
10.1101/2022.12.03.519007 — Posted: 2022-12-07
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine
Dayan, G. H., Rouphael, N., Walsh, S. R., Chen, A., Grunenberg, N., Allen, M., Antony, J., Asante, K. P., Suresh Bhate, A., Beresnev, T., Bonaparte, M. I., Angeles Ceregido, M., Dobrianskyi, D., Fu, B., Grillet, M.-H., Keshtkar-Jahromi, M., Juraska, M., Jin Kee, J., Kibuuka, H., Koutsoukos, M., Masotti, R., Michael, N. L., Reynales, H., Robb, M. L., Villagomez Martinez, S. M., Sawe, F., Schuerman, L., Tong, T., Treanor, J., Wartel, T. A., Diazgranados, C. A., Chicz, R. M., Gurunathan, S., Savarino, S., Sridhar, S., the VAT00008 study team
10.1101/2022.12.05.22282933 — Posted: 2022-12-06
Effectiveness of COVID-19 treatment with nirmatrelvir-ritonavir or molnupiravir among U.S. Veterans: target trial emulation studies with one-month and six-month outcomes
Bajema, K. L., Berry, K., Streja, E., Rajeevan, N., Li, Y., Yan, L., Cunningham, F., Hynes, D. M., Rowneki, M., Bohnert, A., Boyko, E. J., Iwashyna, T. J., Maciejewski, M. L., Osborne, T. F., Viglianti, E. M., Aslan, M., Huang, G. D., Ioannou, G. N.
10.1101/2022.12.05.22283134 — Posted: 2022-12-06
Preferences of health care workers using tongue swabs for tuberculosis diagnosis during COVID-19
Codsi, R., Errett, N. A., Luabeya, A. K., Hatherill, M., Shapiro, A. E., Lochner, K. A., Vingino, A. R., Kohn, M. J., Cangelosi, G. A.
10.1101/2022.12.06.22283185 — Posted: 2022-12-06
Heterologous boosting of neutralizing activity against Delta and Omicron SARS-CoV-2 variants in CoronaVac-primed adults; a randomized study with SCB-2019 vaccine
Rao, C. C., de Los Reyes, M. R. A., Plennevaux, E., Smolenov, I., Hu, B., Gao, F., Ilagan, H., Ambrosino, D., Siber, G., Clemens, R.
10.1101/2022.12.06.22283103 — Posted: 2022-12-06
Genome charaterization based on the Spike-614 and NS8-84 loci of SARS-CoV-2 reveals two major onsets of the COVID-19 pandemic
Zhang, J., Hu, X., Mu, Y., Deng, R., Yi, G., Yao, L.
10.1101/2022.12.04.519037 — Posted: 2022-12-06
Superiority of intranasal over systemic administration of bioengineered soluble ACE2 for survival and brain protection against SARS-CoV-2 infection
Hassler, L., Wysocki, J., Ahrendsen, J. T., Ye, M., Gelarden, I., Nicolaescu, V., Tomatsidou, A., Gula, H., Cianfarini, C., Khurram, N., Kanwar, Y., Singer, B. D., Randall, G., Missiakas, D. M., Henkin, J., Batlle, D.
10.1101/2022.12.05.519032 — Posted: 2022-12-06

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).